{"id":38537,"date":"2026-05-21T10:34:00","date_gmt":"2026-05-21T14:34:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38537"},"modified":"2026-04-27T21:57:25","modified_gmt":"2026-04-28T01:57:25","slug":"the-drug-patent-cliff-a-procurement-managers-sourcing-playbook","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-drug-patent-cliff-a-procurement-managers-sourcing-playbook\/","title":{"rendered":"The Drug Patent Cliff: A Procurement Manager’s Sourcing Playbook"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

How to turn expiring blockbusters into budget wins \u2014 before your competitors do<\/em><\/p>\n\n\n\n

\n\n\n\n

Patent cliffs don’t sneak up on anyone. The data has been public for years. The filing dates are recorded. The expiration math is elementary. Yet procurement teams at health systems, pharmacy benefit managers (PBMs), and group purchasing organizations (GPOs) consistently leave millions on the table by reacting to generic entry rather than anticipating it.<\/p>\n\n\n\n

This is a sourcing playbook for professionals who want to stop reacting. It covers the mechanics of pharmaceutical patent law, the intelligence tools that surface expiration timelines before they hit the trade press, the contracting strategies that convert cliff events into cost-per-patient reductions, and the supply chain realities that determine whether first-day generic availability is a promise or a fantasy.<\/p>\n\n\n\n

The focus is applied and specific. Real drugs, real litigation timelines, real market-entry dynamics.<\/p>\n\n\n\n

\n\n\n\n

Part I: The Cliff Defined \u2014 What Expires, When, and Why It Matters<\/strong><\/h2>\n\n\n\n

The Anatomy of a Drug Patent<\/strong><\/h3>\n\n\n\n

A pharmaceutical product rarely rests on a single patent. By the time a brand-name drug reaches its peak revenue years, its innovator has typically filed a layered portfolio of intellectual property designed to extend commercial exclusivity well beyond the original compound patent. Understanding that structure is the first job of any procurement analyst doing competitive intelligence on a therapy class.<\/p>\n\n\n\n

The foundational document is the U.S. Food and Drug Administration’s Orange Book, formally titled ‘Approved Drug Products with Therapeutic Equivalence Evaluations.’ The Orange Book lists every patent a brand manufacturer has associated with an approved New Drug Application (NDA), along with the expiration dates those patents carry and the type of protection each provides [1]. A drug can have dozens of Orange Book-listed patents covering the active pharmaceutical ingredient (API), specific salt or polymorph forms, formulation characteristics (tablet coating, release mechanism), manufacturing processes, and particular therapeutic uses.<\/p>\n\n\n\n

Each of those patent types has different legal weight in the context of generic entry. An API patent that expires in 2026 is categorically different from a method-of-use patent that expires in 2031, because a generic manufacturer can legally carve out a patented indication from its labeling \u2014 what the industry calls a ‘skinny label’ \u2014 and market the drug for non-patented uses while litigation on the use patent continues [2].<\/p>\n\n\n\n

The Orange Book also lists exclusivity periods separate from patents. These are regulatory grants, not intellectual property rights, and they run concurrently with or sometimes outlast the underlying patents. The main ones a procurement analyst needs to track are:<\/p>\n\n\n\n

    \n
  • New Chemical Entity (NCE) exclusivity:<\/strong> Five years from approval, granted to drugs with an active moiety that has never been approved. Generics cannot submit an Abbreviated New Drug Application (ANDA) during this period, with a narrow exception allowing filings in year four with a six-month delay to approval.<\/li>\n\n\n\n
  • Three-year clinical exclusivity:<\/strong> Granted when a sponsor submits new clinical data supporting a labeling change, such as a new indication or a new patient population. Generic manufacturers can file ANDAs during this period but cannot receive final approval until the exclusivity expires.<\/li>\n\n\n\n
  • Orphan drug exclusivity:<\/strong> Seven years of market exclusivity for drugs treating rare diseases, which can block generic approval even if the patent has expired.<\/li>\n\n\n\n
  • Pediatric exclusivity:<\/strong> A six-month extension added to any existing patent or exclusivity period when a manufacturer conducts FDA-requested pediatric studies. On a blockbuster, this six months can represent hundreds of millions in additional branded revenue [3].<\/li>\n<\/ul>\n\n\n\n

    Stacking these exclusivities is a documented industry practice. AstraZeneca’s esomeprazole (Nexium) is the canonical example: after the base omeprazole patents expired and generic omeprazole flooded the market, AstraZeneca launched the single-isomer esomeprazole on new compound patents, securing additional years of exclusivity on what is chemically the S-enantiomer of the same proton pump inhibitor [4]. Procurement teams at hospital systems who didn’t track that distinction kept paying branded prices for a therapy class where generic competition existed in a related compound.<\/p>\n\n\n\n

    The Numbers Behind the Cliff<\/strong><\/h3>\n\n\n\n

    The phrase ‘patent cliff’ entered widespread use in the early 2010s, when the pharmaceutical industry faced a confluence of major expirations that analysts estimated would put roughly $250 billion in branded drug revenue at risk between 2010 and 2015 [5]. Blockbusters like atorvastatin (Lipitor), clopidogrel (Plavix), and esomeprazole (Nexium) all lost patent protection within a compressed window.<\/p>\n\n\n\n

    The industry adapted. Branded manufacturers accelerated their pipeline diversification, pursued biosimilar strategies for existing biologics, and \u2014 critically \u2014 got better at evergreening through secondary patents and reformulations. What followed the initial cliff was not a clean market transition but a rolling, drug-by-drug negotiation between innovators trying to extend commercial life and generic manufacturers trying to enter as early as legally possible.<\/p>\n\n\n\n

    The current wave is no less consequential. Between 2025 and 2030, drugs representing an estimated $236 billion in annual global sales are expected to face loss of exclusivity (LOE) [6]. The list includes immunology blockbusters, oncology agents, and GLP-1 receptor agonists that have become the fastest-growing drug class in pharmacy benefit history. <blockquote> ‘Loss of exclusivity events affecting approximately $236 billion in annual sales are projected between 2025 and 2030, with biologics and biosimilars accounting for a growing share of that exposure.’ \u2014 IQVIA Institute for Human Data Science, ‘The Use of Medicines in the U.S. 2024’ [6] <\/blockquote><\/p>\n\n\n\n

    For procurement teams, the operative question is not the global revenue number but the per-claim cost reduction achievable at their specific patient population and contract structure. A hospital system managing a formulary for a Medicaid-heavy population has different exposure to patent cliff events than a self-insured employer whose covered population skews toward commercially insured adults in the 45\u201365 demographic. The strategic posture differs accordingly.<\/p>\n\n\n\n

    Small Molecule vs. Biologic Patents: A Procurement-Relevant Distinction<\/strong><\/h3>\n\n\n\n

    The mechanism of generic entry differs fundamentally between small-molecule drugs and biologics, and that difference shapes every downstream contracting decision.<\/p>\n\n\n\n

    For small molecules, the Hatch-Waxman Act of 1984 created a streamlined pathway for ANDA approval, allowing generics to rely on the brand’s clinical safety and efficacy data if they can demonstrate bioequivalence. When the relevant Orange Book patents expire (or are successfully challenged), the FDA can approve generic versions that are therapeutically equivalent to the reference listed drug (RLD). Formulary substitution is generally automatic, and generic market share typically reaches 80\u201390% of volume within 12 months of entry [7].<\/p>\n\n\n\n

    Biologics operate differently. The Biologics Price Competition and Innovation Act (BPCIA) of 2009 created a separate 351(k) pathway for biosimilar approval, but the complexity of biologic manufacturing, the 12-year reference product exclusivity period, and the multi-step ‘patent dance’ information-exchange process between innovator and biosimilar applicant produce timelines that are structurally longer and litigation outcomes that are harder to predict than in the small-molecule ANDA world [8].<\/p>\n\n\n\n

    The clinical and regulatory distinction between ‘biosimilar’ and ‘interchangeable biosimilar’ matters for procurement because only interchangeable biosimilars \u2014 those that have met FDA’s additional switching study requirements \u2014 can be substituted by pharmacists without prescriber authorization in most states. That distinction affects whether a formulary management strategy can rely on automatic substitution or requires active prescriber engagement.<\/p>\n\n\n\n

    Humira (adalimumab), AbbVie’s TNF inhibitor, provides the most studied recent example of how biologic patent cliffs play out. AbbVie’s patent portfolio on Humira was extraordinarily dense \u2014 more than 130 patents, earning it the nickname ‘patent thicket’ among IP analysts. The company entered licensing agreements with biosimilar developers that delayed U.S. market entry until January 2023, despite European biosimilar competition beginning in 2018 [9]. When U.S. biosimilars did enter, pharmacy benefit managers and large health system procurement teams that had pre-negotiated biosimilar preference arrangements captured cost reductions approaching 85% versus the branded list price on some formulations \u2014 while plans that hadn’t done the pre-work faced contract complexity that slowed their formulary transitions [10].<\/p>\n\n\n\n

    \n\n\n\n

    Part II: Intelligence Infrastructure \u2014 How to Track What’s Expiring<\/strong><\/h2>\n\n\n\n

    The Orange Book as a Primary Source<\/strong><\/h3>\n\n\n\n

    The FDA’s Orange Book is the foundational public data source for small-molecule patent and exclusivity tracking. It is searchable at the FDA’s website and updated daily. For any ANDA-pathway product, a procurement analyst can query the Orange Book by active ingredient, brand name, or NDA number and retrieve the full list of associated patents with their expiration dates, patent use codes, and whether each patent is subject to a Paragraph IV certification challenge [1].<\/p>\n\n\n\n

    The critical discipline is knowing which Orange Book entries to weight heavily and which to treat as lower-probability barriers to generic entry. A compound patent with a 2026 expiration date and no pending litigation creates a clear sourcing opportunity. The same expiration date attached to a patent that is currently the subject of Paragraph IV litigation \u2014 where the generic applicant has certified the patent is either invalid or will not be infringed \u2014 creates a more complex probability analysis.<\/p>\n\n\n\n

    Patent use codes are underutilized by procurement teams. The FDA assigns each Orange Book patent a ‘U-code’ that describes the specific claimed use. When a generic files a skinny label carving out a patented indication, the applicable use codes tell you whether the carved-out use represents a significant portion of prescribing volume. A drug used primarily off-label for an unpatented indication may be substitutable far sooner than the listed patent expiration suggests.<\/p>\n\n\n\n

    The 30-Month Stay and Its Sourcing Implications<\/strong><\/h3>\n\n\n\n

    When a generic manufacturer files an ANDA containing a Paragraph IV certification, the brand manufacturer has 45 days to file an infringement suit. If it does, the FDA automatically imposes a 30-month stay on ANDA approval, meaning the generic cannot launch until either the litigation resolves in the generic’s favor or 30 months pass, whichever comes first [11].<\/p>\n\n\n\n

    For procurement planning, the 30-month stay is both a risk and a signal. It tells you that at least one generic manufacturer has decided the relevant patent is either invalid or non-infringed \u2014 a legal bet with real financial stakes. Generic companies don’t file Paragraph IV certifications idly; the litigation costs and commercial preparation required to go to market make each certification a deliberate investment.<\/p>\n\n\n\n

    Multiple ANDAs with Paragraph IV certifications on the same product compound the competitive pressure on the brand. When four or five generics have all certified and are actively litigating, the probability of at least one prevailing increases substantially. Procurement teams should track the number of Paragraph IV filers on any target product, not just the single first-filer who gets 180-day exclusivity on generic entry.<\/p>\n\n\n\n

    The 180-day first-filer exclusivity is another mechanism worth tracking precisely. The first ANDA applicant to file a Paragraph IV certification for each Orange Book-listed patent gets a 180-day period of generic exclusivity during which the FDA cannot approve competing ANDAs. After that window closes, the market opens to all approved generics. The pricing dynamics during that 180-day period differ markedly from the broader generic market: a single generic entrant rarely drives price as low as a market with four or five competitors, so procurement timing relative to that window affects achievable discounts [12].<\/p>\n\n\n\n

    DrugPatentWatch: Structured Patent Intelligence at the NDA Level<\/strong><\/h3>\n\n\n\n

    The Orange Book gives you the official record. What it doesn’t give you is context: litigation history, settlement terms, ANDA filing counts, 180-day exclusivity triggers, or the probabilistic timeline modeling that procurement decisions actually require.<\/p>\n\n\n\n

    DrugPatentWatch fills much of that gap. The platform aggregates Orange Book data with ANDA filing records, litigation dockets, settlement notices, and FDA approval actions to produce timeline estimates for when a given drug is likely to face generic entry. For procurement teams building multi-year drug spend projections, DrugPatentWatch’s database lets analysts identify products approaching patent expiration across their entire formulary \u2014 not just the headline blockbusters that appear in trade press, but the mid-tier products that collectively represent significant spend without attracting the same attention.<\/p>\n\n\n\n

    A practical use case: a GPO analyst reviewing the therapy class for CGRP-pathway migraine treatments can use DrugPatentWatch to examine the Orange Book patents for erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality), cross-reference the 12-year biologic exclusivity periods derived from their approval dates, and model the earliest possible biosimilar entry dates \u2014 even when no biosimilar applicant has yet filed [13]. That forward modeling changes how the GPO structures its current contracting with the brand manufacturers: if exclusivity on a given product runs through 2031, you negotiate differently than if the exclusivity window closes in 2028.<\/p>\n\n\n\n

    The platform also tracks what it terms ‘patent expiration alerts’ \u2014 automated notifications when a specific product’s listed patents approach expiration or when a Paragraph IV certification triggers a litigation event. For procurement professionals managing a portfolio of hundreds of formulary products, that alert infrastructure is the difference between proactive sourcing and reactive response.<\/p>\n\n\n\n

    ANDA and BLA Pipeline Visibility<\/strong><\/h3>\n\n\n\n

    FDA’s public records of generic and biosimilar applications provide a second intelligence stream. The FDA’s ANDA approval actions database, updated monthly, lists approvals by NDA number, active ingredient, and strength. When generics start receiving approvals on a product where you’ve been tracking litigation, that’s your signal to begin formal sourcing.<\/p>\n\n\n\n

    For biosimilars, the Purple Book (FDA’s equivalent of the Orange Book for biologic products) lists reference products, their exclusivity dates, and approved biosimilars with their interchangeability designations [14]. The Purple Book doesn’t list all pending applications, but the FDA’s Biosimilar Product Development (BPD) meeting list \u2014 which records companies that have formally requested guidance meetings with FDA \u2014 functions as a leading indicator of biosimilar pipeline depth for any given reference product.<\/p>\n\n\n\n

    IQVIA Institute publishes an annual ‘Biosimilars in the United States’ report that cross-references Purple Book data with real-world dispensing volume to show actual market penetration rates by product. That data is essential for calibrating expectations: the biosimilar market in the U.S. has historically underperformed European analogues due to contracting structures, formulary barriers, and litigation, so European penetration rates are an optimistic upper bound on what U.S. procurement teams should model [15].<\/p>\n\n\n\n

    Court Dockets and Settlement Monitoring<\/strong><\/h3>\n\n\n\n

    Patent litigation outcomes are public records. PACER (Public Access to Court Electronic Records) contains the full docket history for every Hatch-Waxman case filed in U.S. federal courts. A litigation analyst comfortable with PACER can track the procedural status of any active case \u2014 scheduling orders, claim construction rulings, summary judgment decisions \u2014 and convert those milestones into probability-weighted timeline estimates.<\/p>\n\n\n\n

    For procurement professionals who don’t have in-house IP litigation expertise, third-party litigation tracking services like Docket Alarm or Bloomberg Law’s patent litigation module provide more accessible interfaces to the same underlying records. The key data points to extract are: whether a consent order (settlement with negotiated entry date) has been filed, what the stipulated entry date is, and whether any ‘at-risk’ launch provisions exist that would allow the generic to launch before final resolution.<\/p>\n\n\n\n

    At-risk launches \u2014 where a generic enters the market before a court has finally adjudicated the patent dispute \u2014 are high-volatility events for both sides. The generic manufacturer risks substantial damages if it ultimately loses. The brand risks rapid market share loss. For procurement teams, an at-risk launch by a credible generic manufacturer is a direct signal to begin competitive bidding, even if the legal outcome remains uncertain. AbbVie’s experience with adalimumab biosimilars and Amgen’s at-risk launch of its biosimilar in January 2023 illustrates the scale: Amgen launched Amjevita at two price points \u2014 a 5% discount and an 80% discount to Humira’s list price \u2014 a dual-pricing strategy that immediately forced procurement teams to choose their contracting architecture [10].<\/p>\n\n\n\n

    \n\n\n\n

    Part III: The Regulatory Mechanics of Generic and Biosimilar Entry<\/strong><\/h2>\n\n\n\n

    ANDA Approval Timelines: What the FDA Numbers Actually Show<\/strong><\/h3>\n\n\n\n

    The FDA’s Center for Drug Evaluation and Research (CDER) publishes annual performance metrics on generic drug review. The target review time for a priority generic application is 10 months from filing; for a standard ANDA, it’s 12 months [16]. In practice, the time from first ANDA filing to final approval \u2014 accounting for complete response letters, amendment cycles, and facility inspection requirements \u2014 has historically stretched well beyond those targets for complex products.<\/p>\n\n\n\n

    FDA’s Generic Drug Program has made substantial progress on review backlogs since Congress passed the Generic Drug User Fee Act (GDUFA) in 2012, which tied industry fees to performance goals. First-cycle approval rates \u2014 the fraction of applications approved without a complete response letter \u2014 have improved, and the number of pending ANDAs awaiting approval has declined from a peak of more than 4,000 in 2016 to substantially lower levels [17]. But complex products \u2014 extended-release formulations, combination products, sterile injectables, transdermal systems \u2014 still carry longer approval timelines and higher rejection rates than simple oral solid-dose generics.<\/p>\n\n\n\n

    For procurement planning, that means the type of product matters as much as the patent expiration date. An immediate-release oral tablet with a well-characterized API and multiple ANDA filers may have generic availability within months of patent expiration. A transdermal patch, a complex suspension, or a sterile ophthalmic product may face a one-to-three year gap between patent expiration and first generic approval, even with multiple applicants in queue.<\/p>\n\n\n\n

    The 505(b)(2) Pathway and Its Procurement Implications<\/strong><\/h3>\n\n\n\n

    Not every branded-to-generic transition involves a straightforward ANDA. The FDA’s 505(b)(2) approval pathway, available to products that are not identical to the reference listed drug, allows applicants to rely partially on existing published literature and partially on their own data. It is the pathway used for new formulations, new dosage forms, and new delivery systems based on approved active ingredients.<\/p>\n\n\n\n

    From a procurement standpoint, 505(b)(2) products occupy an ambiguous competitive position. They are not therapeutically equivalent to the original NDA product in the same way ANDA generics are, so automatic pharmacist substitution doesn’t apply. But they often represent clinically acceptable alternatives that formulary committees can prefer. Extended-release formulations of methylphenidate, for instance, created multiple branded 505(b)(2) competitors after the immediate-release compound lost patent protection, fragmenting the market in ways that complicated formulary management.<\/p>\n\n\n\n

    The therapeutic equivalence rating in the Orange Book \u2014 the AB code \u2014 is the determinant of whether a product can be auto-substituted. Procurement teams should verify AB ratings before relying on substitution volume assumptions in their financial models.<\/p>\n\n\n\n

    Biosimilar Interchangeability: The Substitution Threshold That Changes Everything<\/strong><\/h3>\n\n\n\n

    The FDA’s definition of ‘interchangeable’ biosimilar is specific and consequential. Under the BPCIA, a biosimilar is interchangeable if it produces the same clinical result as the reference product in any given patient and if the risk of alternating between the reference product and the biosimilar is not greater than the risk of using the reference product alone [8].<\/p>\n\n\n\n

    To achieve an interchangeability designation, a manufacturer must conduct switching studies \u2014 typically three-arm crossover trials that expose patients to alternating treatment with the reference product and the biosimilar. Those studies add cost and time to the development program. As of early 2025, the FDA had designated fewer than 15 biosimilars as interchangeable, out of more than 40 approved biosimilars in total [14].<\/p>\n\n\n\n

    The commercial significance of interchangeability is state-dependent. Most states have enacted laws governing pharmacist substitution of biosimilars, and the majority require interchangeability designation before substitution without prescriber authorization. In states where interchangeability is required for substitution and the available biosimilar lacks that designation, formulary conversion requires active prescriber engagement \u2014 a materially different operational challenge from auto-substitution.<\/p>\n\n\n\n

    California, Texas, and New York \u2014 three states with large commercially insured populations \u2014 all have substitution laws that apply only to interchangeables. Procurement teams at health plans with significant membership in those states need to map their biosimilar formulary strategy against the interchangeability status of available products, not just against biosimilar approval status.<\/p>\n\n\n\n

    The FDA’s Complex Drug Approval Landscape<\/strong><\/h3>\n\n\n\n

    Several drug categories present particular challenges for generic entry that procurement teams routinely underestimate:<\/p>\n\n\n\n

    Inhaled products<\/strong> (metered-dose inhalers, dry powder inhalers): FDA requires in vitro and in vivo equivalence data that goes beyond standard bioequivalence testing, because lung deposition characteristics matter to clinical outcome. Generic COPD and asthma inhalers have faced notably long development and approval timelines relative to oral solid-dose generics. The budesonide\/formoterol combination (Symbicort), for example, did not receive its first generic equivalent until 2019, several years after the API patents expired [18].<\/p>\n\n\n\n

    Dermatological products<\/strong> (topical creams, ointments, gels): FDA’s dermatology generics program has historically struggled with bioequivalence methodology. The agency developed in vitro permeation testing (IVPT) and in vitro release testing (IVRT) frameworks to reduce the reliance on costly and variable in vivo skin pharmacokinetics studies, but the science remains contested for some product types. Procurement teams should not assume topical patent expirations translate to timely generic availability without verifying the ANDA pipeline depth.<\/p>\n\n\n\n

    Complex injectables<\/strong> (liposomes, nanoparticles, emulsions): FDA’s regulatory framework for demonstrating sameness in complex injectable formulations is still evolving. Doxorubicin hydrochloride liposome injection (Doxil) is the reference case: its first generic equivalent was not approved until 2013, more than a decade after the compound’s basic patent expired, largely because of formulation complexity and the FDA’s difficulty establishing bioequivalence standards [19].<\/p>\n\n\n\n

    \n\n\n\n

    Part IV: The Cliff Event \u2014 What Actually Happens at Expiration<\/strong><\/h2>\n\n\n\n

    Day-One Generic Entry: The Competitive Cascade<\/strong><\/h3>\n\n\n\n

    When a patent expires without active litigation, or when litigation concludes with a generic win, the FDA can approve ANDAs that have been pending in the queue. Multiple generics may launch simultaneously, or within days of each other, depending on 180-day exclusivity dynamics. The pricing behavior that follows is rapid and well-documented.<\/p>\n\n\n\n

    With a single generic entrant, retail and institutional pricing typically lands 20\u201340% below the brand’s average wholesale price (AWP). That discount widens as additional generics enter: with four or more competitors, pricing commonly falls to 80\u201395% below branded AWP for mature, high-volume products [7]. The compression happens quickly \u2014 often within six months of multi-source generic entry.<\/p>\n\n\n\n

    Procurement teams at health systems and PBMs who have pre-negotiated maximum allowable cost (MAC) policies or generic effective rate (GER) guarantees in their pharmacy contracts are positioned to capture that pricing immediately. Teams who haven’t done that contracting work in advance discover they’re negotiating from the buyer’s position, but with counterparties who already have multiple other customers competing for supply.<\/p>\n\n\n\n

    The supply side matters as much as the demand side. When a blockbuster loses exclusivity, the initial wave of generic demand frequently exceeds manufacturing capacity. Generic manufacturers who have been approved but who haven’t ramped up production \u2014 because doing so before approval carries financial risk \u2014 face allocation pressures. Shortages of newly genericized products within the first 12\u201318 months of generic entry are common enough that procurement teams should build contingency sourcing plans, not just price targets.<\/p>\n\n\n\n

    Brand Manufacturer Responses to Generic Entry<\/strong><\/h3>\n\n\n\n

    Innovator companies have developed a predictable set of responses to approaching cliff events, and recognizing them helps procurement teams anticipate the contracting moves they’ll face.<\/p>\n\n\n\n

    Authorized generics:<\/strong> The most direct response. A brand manufacturer licenses a version of its own drug to a generic company (or its own subsidiary) to launch simultaneously with the first ANDA generic. The authorized generic competes with the Paragraph IV filer for market share, defeating the 180-day exclusivity window because the authorized generic is not an ANDA product and is not subject to the exclusivity. From a procurement standpoint, the authorized generic provides an immediate source of price competition and an alternative to the Paragraph IV filer whose supply ramp may be slower.<\/p>\n\n\n\n

    Brand-to-generic pricing signals:<\/strong> Some innovator companies launch their own over-the-counter versions or store-brand equivalents of prescription drugs approaching patent expiration, repositioning the product to capture a different consumer segment. Proton pump inhibitors followed this trajectory extensively.<\/p>\n\n\n\n

    Reformulation and line extension:<\/strong> If the innovator has a next-generation formulation \u2014 extended-release, fixed-dose combination, new delivery system \u2014 approaching expiration is the moment to accelerate its commercial adoption. The strategy is to shift prescribers toward the reformulated product before generic competition arrives on the original, effectively resetting the competitive clock. Procurement teams who don’t recognize this transition often continue authorizing the reformulation at branded prices while the original compound becomes available generically.<\/p>\n\n\n\n

    Defensive contracting:<\/strong> As a product approaches LOE, brand manufacturers typically escalate rebate offers to PBMs, health plans, and GPOs to maintain preferred formulary status. Those rebates are real money in the short term, but they should be modeled against the total cost of delayed generic conversion \u2014 because a rebated brand price, even at a substantial discount, typically remains well above the multi-source generic price achievable 12\u201318 months post-LOE [20].<\/p>\n\n\n\n

    Managed Care Formulary Transitions: The P&T Calendar Problem<\/strong><\/h3>\n\n\n\n

    Pharmacy and Therapeutics (P&T) committees typically meet quarterly. That meeting cadence creates a structural lag between when procurement teams have actionable intelligence on generic entry and when formulary changes can take effect.<\/p>\n\n\n\n

    A generic that receives FDA approval in March may not make it onto the formulary until the June P&T meeting, with implementation in August. During that gap, the health system or plan continues paying branded prices \u2014 or 180-day exclusivity single-source generic prices \u2014 for a product that should be in a competitive multi-source market. Multiplied across a formulary of hundreds of products, that lag represents recoverable cost.<\/p>\n\n\n\n

    The solution is not to bypass P&T, which serves an essential clinical quality function. The solution is to build a prospective patent expiration calendar into the P&T committee’s standing agenda. Most P&T committees address formulary management reactively, responding to new product approvals and drug safety signals. Adding a forward-looking patent expiration agenda item \u2014 reviewed quarterly against DrugPatentWatch data and FDA ANDA pipeline information \u2014 allows the committee to pre-authorize formulary transitions that become effective the moment generic availability is confirmed, rather than waiting for the next meeting cycle after the fact.<\/p>\n\n\n\n

    Hospital System-Specific Cliff Dynamics<\/strong><\/h3>\n\n\n\n

    Hospitals and health systems face cliff dynamics that differ from retail pharmacy and PBM contexts in several ways.<\/p>\n\n\n\n

    Drug shortages hit hospital formularies harder. Injectable generics, parenteral nutrition components, and sterile preparations account for a disproportionate share of hospital pharmaceutical spend and carry higher shortage risk than oral solid dosage forms. A newly genericized injectable that experiences supply disruption doesn’t have a retail pharmacy as a backup \u2014 the hospital formulary committee has to manage the shortage actively, often paying shortage premiums or accepting therapeutic substitutes [21].<\/p>\n\n\n\n

    340B program implications are non-trivial. Hospitals operating under the 340B Drug Pricing Program are entitled to purchase certain outpatient drugs at substantially reduced prices. The 340B ceiling price calculation is based on AMP (Average Manufacturer Price) and varies by drug; generic entry that reduces AMP can alter the 340B ceiling price in ways that affect hospital purchasing economics. Procurement teams at 340B-covered entities should model the impact of generic entry on their 340B eligible drug costs alongside the standard WAC-to-generic price reduction analysis.<\/p>\n\n\n\n

    \n\n\n\n

    Part V: The Biosimilar Cliff \u2014 Different Mechanics, Same Imperative<\/strong><\/h2>\n\n\n\n

    Humira Biosimilars: A Case Study in Market Structure<\/strong><\/h3>\n\n\n\n

    AbbVie’s adalimumab (Humira) achieved peak annual U.S. net revenues of approximately $17.7 billion in 2021, making it the best-selling drug in history by many measures [22]. The IP protection strategy that sustained that revenue \u2014 a portfolio of more than 130 patents covering not just the antibody but its manufacturing, formulation, and specific administration devices \u2014 became the reference case for biologic patent thicket strategies.<\/p>\n\n\n\n

    The settlement agreements AbbVie negotiated with biosimilar developers delayed U.S. market entry until January 2023, while European competition had been established since 2018. When biosimilars did enter the U.S. market in 2023, they entered in a group: Amgen’s Amjevita, Sandoz’s Hyrimoz, Boehringer Ingelheim’s Cyltezo (the first interchangeable adalimumab biosimilar), and several others arrived within months of each other [23].<\/p>\n\n\n\n

    The market structure that emerged illustrates the complexity of biologic patent cliff management for procurement teams:<\/p>\n\n\n\n

      \n
    1. High-concentration formulations (adalimumab 100 mg\/mL, which allows injection in smaller volumes) were initially only available in the brand and a subset of biosimilars, creating formulary management complexity for patients who had been titrated to the high-concentration form.<\/li>\n\n\n\n
    2. Amgen’s dual-pricing strategy \u2014 its 5% list price discount for plans with existing brand rebate contracts and its 80% discount for plans willing to shift formulary \u2014 forced procurement teams to make an explicit strategic choice between short-term rebate revenue and long-term unit cost reduction.<\/li>\n\n\n\n
    3. PBMs that had long-term rebate contracts with AbbVie faced contractual constraints on formulary conversion that limited their ability to pass biosimilar savings to plan sponsors immediately.<\/li>\n<\/ol>\n\n\n\n

      The net result, in the first year of biosimilar competition, was a less dramatic market conversion than many analysts had predicted. Health plans that had done advance planning \u2014 renegotiating PBM contracts, identifying interchangeable biosimilars, pre-authorizing formulary exceptions \u2014 captured larger savings earlier [24].<\/p>\n\n\n\n

      GLP-1 Receptor Agonists: The Next Major Biologic Patent Horizon<\/strong><\/h3>\n\n\n\n

      The GLP-1 receptor agonist class \u2014 dominated by semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) \u2014 has grown to represent one of the fastest-rising drug cost categories for pharmacy benefit managers and health plans. Understanding the IP landscape for this class is essential for any procurement team managing a formulary that covers obesity or type 2 diabetes.<\/p>\n\n\n\n

      Novo Nordisk’s semaglutide products carry compound patent protection that extends into the early 2030s in the U.S. The core semaglutide compound patent (U.S. Patent No. 9,901,623) has an expiration date in January 2032, though additional formulation and delivery device patents complicate that timeline [25]. Several companies, including Teva and Sun Pharma, have publicly signaled interest in biosimilar or generic semaglutide development, but no 351(k) biosimilar application for semaglutide had received FDA approval as of early 2025.<\/p>\n\n\n\n

      Eli Lilly’s tirzepatide presents a different IP structure. As a dual GIP\/GLP-1 agonist \u2014 technically a distinct mechanism from pure GLP-1 agonists \u2014 tirzepatide’s compound patent protection runs to the early-to-mid 2030s. Lilly has pursued aggressive line extension strategies, filing for and receiving approval for separate NDAs for the diabetes indication (Mounjaro) and the obesity indication (Zepbound) at doses that differ from the diabetes NDA [26].<\/p>\n\n\n\n

      For procurement teams managing these products today, the actionable insight from the patent timeline is not ‘wait for generics.’ It’s ‘use the patent horizon to structure competitive negotiations between branded alternatives and to evaluate compound pharmacy and 503B outsourcing risk in states where it exists.’ Compounding pharmacies have produced semaglutide preparations under a temporary FDA shortage designation \u2014 a situation that created cost arbitrage for some plans and clinical risk questions for others. That dynamic will shift as branded supply normalizes and FDA pursues enforcement against non-exempt compounders [27].<\/p>\n\n\n\n

      Oncology Biologics: The Biosimilar Adoption Lag<\/strong><\/h3>\n\n\n\n

      In oncology, biosimilar adoption has lagged behind other therapy areas despite substantial approved biosimilar portfolios for products like trastuzumab (Herceptin), bevacizumab (Avastin), and rituximab (Rituxan). The reasons are structural and specific to oncology care delivery.<\/p>\n\n\n\n

      Buy-and-bill reimbursement \u2014 where oncologists purchase infusion drugs and bill payers for drug cost plus an administration fee \u2014 creates physician-level financial incentives that can run counter to formulary biosimilar conversion. Because Medicare Part B reimbursement for physician-administered drugs is typically set at ASP (Average Sales Price) plus 6%, a biosimilar with a lower ASP generates lower absolute dollar margin per infusion than the originator, even if the percentage markup is the same. That arithmetic doesn’t justify resisting biosimilar adoption from a clinical standpoint, but it creates friction that procurement teams at health systems need to address through physician engagement and alignment structures, not just formulary edicts [28].<\/p>\n\n\n\n

      The Inflation Reduction Act introduced provisions designed to address this \u2014 specifically, a payment differential for biosimilars in Part B \u2014 but implementation details continue to evolve. Procurement teams at academic medical centers and oncology practice groups should monitor CMS guidance on biosimilar payment policy alongside the standard IP cliff tracking work.<\/p>\n\n\n\n

      \n\n\n\n

      Part VI: Contracting Strategies for the Pre-Cliff Window<\/strong><\/h2>\n\n\n\n

      Timing the Generic Sourcing Event<\/strong><\/h3>\n\n\n\n

      The optimal contracting window for generic drugs is not at the moment of patent expiration. It is 6\u201312 months in advance, when the procurement team can use its forward intelligence to create competitive pressure on existing brand contracts while simultaneously positioning for the generic launch.<\/p>\n\n\n\n

      Here’s the logic: a brand manufacturer’s willingness to negotiate rebates and price concessions increases as the probability of generic entry becomes credible. In the 12-month window before a major expiration \u2014 particularly when Paragraph IV litigation is resolving in the generic’s favor or when multiple ANDA approvals are imminent \u2014 the brand has maximum incentive to lock in volume before market share collapses. A procurement team that brings verifiable intelligence (ANDA approval timelines, litigation status, 180-day exclusivity analysis) to that negotiation is negotiating from a position of informed leverage.<\/p>\n\n\n\n

      The parallel work is qualifying generic suppliers in advance. GPOs and large health systems can issue RFPs to generic manufacturers before FDA approval, contingent on approval and commercial launch. That pre-approval contracting captures committed pricing before the market fully clears \u2014 particularly valuable in the 180-day exclusivity window, when only one generic manufacturer can ship.<\/p>\n\n\n\n

      Sourcing Multi-Source Generics: The Supplier Concentration Problem<\/strong><\/h3>\n\n\n\n

      Generic pharmaceutical supply concentration is a chronic procurement risk that patent cliff events tend to expose. When a product achieves robust multi-source competition and prices fall to commodity levels, manufacturing economics become challenging for smaller producers. The result is supplier attrition \u2014 manufacturers exit the market, and what begins as a six-supplier competitive market consolidates to two or three over three to five years [29].<\/p>\n\n\n\n

      At two or three suppliers, a supply disruption at any single manufacturer can trigger shortage conditions and pricing spikes for products that should, in theory, be generic commodities. The FDA tracks drug shortages; its shortage database shows that generic injectable drugs \u2014 which have concentrated API sourcing and complex sterile manufacturing requirements \u2014 account for a disproportionate share of reported shortages [21].<\/p>\n\n\n\n

      The procurement response to supplier concentration risk is dual-source or multi-source contractual requirements backed by real monitoring. A health system that awards 100% of its generic spend on a critical injectable to a single supplier based on best price is optimizing one metric while creating structural fragility. Building a second qualified supplier into the source-of-supply contract, at perhaps a 20\u201330% committed volume share, maintains competitive pricing pressure while preserving supply resilience. The additional cost, where it exists, is properly characterized as supply chain insurance.<\/p>\n\n\n\n

      Formulary Architecture and Tier Placement<\/strong><\/h3>\n\n\n\n

      How a formulary places a generic \u2014 its tier assignment, the associated patient cost-sharing, and whether prior authorization is required for the branded alternative \u2014 determines whether formulary conversion achieves its intended volume shift.<\/p>\n\n\n\n

      For high-volume primary care drugs (statins, ACE inhibitors, beta-blockers, metformin), tier placement is the primary lever. Placing the generic on Tier 1 with $0 or $5 copay while moving the brand to Tier 3 or non-preferred status generates rapid volume conversion in most commercially insured populations. The same strategy for specialty medications \u2014 particularly self-administered injectables \u2014 requires more active clinical management because patient-level factors (injection technique, device familiarity, clinical history) affect switching success rates.<\/p>\n\n\n\n

      In the biosimilar context, non-medical switching \u2014 changing a stable patient’s medication for formulary or cost reasons rather than clinical indication \u2014 is contested by patient advocacy groups and some physician specialty societies. Procurement teams and medical directors at health plans need to address this proactively, with clinical protocols that define appropriate switching criteria and patient monitoring requirements, rather than treating biosimilar conversion as purely an administrative exercise [30].<\/p>\n\n\n\n

      Contract Length and Cliff Event Optionality<\/strong><\/h3>\n\n\n\n

      Long-term supply contracts for drugs approaching patent expiration are high-risk commitments that procurement teams should approach with explicit optionality provisions. A three-year contract signed at current brand pricing for a product where generic entry is probable within 18 months is a money-losing decision regardless of the rebate structure attached to it.<\/p>\n\n\n\n

      The standard contracting mechanism for managing this risk is an ‘at-LOE’ or ‘upon generic entry’ clause that explicitly defines what happens to contract pricing, volume commitments, and formulary status when generic equivalents become available. Negotiating those clauses into brand contracts before generic entry \u2014 rather than trying to renegotiate after the fact \u2014 requires having the patent expiration timeline analysis completed and incorporated into the contracting team’s position well before the LOE event.<\/p>\n\n\n\n

      Some PBM master service agreements now include explicit generic conversion guarantees \u2014 commitments that the PBM will move eligible members to generic alternatives within defined timeframes after generic availability, with financial performance guarantees tied to that conversion rate. Health plan procurement teams negotiating PBM contracts should treat those guarantees as a material term, not a nice-to-have.<\/p>\n\n\n\n

      \n\n\n\n

      Part VII: International Patent Cliff Dynamics and Import Sourcing<\/strong><\/h2>\n\n\n\n

      How Country-Specific Patent Timelines Create Global Arbitrage<\/strong><\/h3>\n\n\n\n

      Patents are national rights, not global ones. A compound patent that expires in the U.S. in 2027 may have already expired in Canada, India, or Brazil \u2014 creating legal manufacturing capacity for generic equivalents that exist internationally but cannot be imported into the U.S. without FDA registration and Hatch-Waxman compliance.<\/p>\n\n\n\n

      Conversely, a U.S. patent expiration can precede market-specific exclusivity protections in the EU, Japan, or emerging markets, creating situations where the U.S. generic market is more competitive than international analogues. European data exclusivity, which runs 10 years from reference product approval (the ‘8+2+1’ framework under European pharmaceutical law), and supplementary protection certificates (SPCs) that extend patent life to compensate for regulatory review time, mean that patent cliff timelines in Europe don’t mirror U.S. timelines for the same products [31].<\/p>\n\n\n\n

      For procurement teams at health systems or plans with international component \u2014 multinational employer groups, globally distributed supply chains \u2014 tracking country-level patent status is a meaningful analytical exercise. But for domestic U.S. procurement, the import pathway creates a different kind of opportunity: FDA-approved API sourcing from manufacturers in India and China, which supply the majority of API inputs for U.S.-finished generic formulations. When a U.S. patent cliff creates new generic demand, the API supply chain response is typically routed through Indian and Chinese API producers who are already FDA-registered and already serving the U.S. generic industry.<\/p>\n\n\n\n

      India’s Pharmaceutical Export Capacity and U.S. Generic Supply<\/strong><\/h3>\n\n\n\n

      India supplies approximately 40% of generic drugs by volume consumed in the U.S., and its pharmaceutical export sector has been central to the cost economics of the U.S. generic market since the 1990s [32]. The FDA has more overseas inspectors stationed in India than in any other country outside the U.S., reflecting both the scale of Indian pharmaceutical production and the historic quality compliance challenges that have required enforcement action at multiple Indian facilities.<\/p>\n\n\n\n

      For procurement teams, the India connection has two procurement-relevant implications. First, Indian API and finished-dose manufacturing capacity is the buffer that absorbs demand spikes when a blockbuster loses exclusivity. When production capacity is tight \u2014 because multiple blockbusters are losing exclusivity simultaneously, or because a large Indian manufacturer has faced an FDA import alert \u2014 allocation pressures emerge across the generic market.<\/p>\n\n\n\n

      Second, geopolitical factors affecting India-U.S. trade relations, regulatory compliance enforcement, and quality system requirements can affect generic supply availability. The COVID-19 period illustrated the fragility of concentrated API sourcing: when Indian API manufacturers faced production disruptions, the downstream effect on U.S. generic availability was rapid and visible. Procurement teams who had diversified their qualified supplier lists or who had secured domestic manufacturing alternatives were insulated from the worst of those shortages.<\/p>\n\n\n\n

      The Specialty Generic Opportunity: Branded Products Without Competition<\/strong><\/h3>\n\n\n\n

      One underappreciated category in patent cliff analysis is specialty generics \u2014 products where the underlying compound is off-patent but where specialty manufacturing requirements, limited market size, or clinical complexity have prevented robust generic competition from developing.<\/p>\n\n\n\n

      Products in this category include certain inhaled drug-device combinations, complex injectables, and specialty oral formulations. Because the market is small or the development cost is high relative to the commodity generic opportunity, generic manufacturers have not invested in ANDA development. The result is a product that is, in principle, off-patent but that faces no generic competition in practice.<\/p>\n\n\n\n

      Procurement teams at large health systems can sometimes move this market themselves. When a health system’s annual spend on an off-patent specialty product is large enough to provide a viable return on ANDA development investment, a targeted procurement process \u2014 issuing an RFI to qualified generic manufacturers and committing to volume in exchange for development effort \u2014 can catalyze generic entry that wouldn’t otherwise occur. This is not a mainstream procurement activity, but it has been executed successfully by large integrated delivery networks working in partnership with generic manufacturers for specific products [33].<\/p>\n\n\n\n

      \n\n\n\n

      Part VIII: The Supply Chain Realities That Determine Whether the Cliff Works For You<\/strong><\/h2>\n\n\n\n

      Shortage Risk as a Patent Cliff Co-Occurrence<\/strong><\/h3>\n\n\n\n

      The relationship between patent cliff events and drug shortages is not accidental. When a product loses exclusivity and generic prices fall rapidly, the branded manufacturer has reduced incentive to maintain production capacity. Generic manufacturers who win ANDA approvals may not have full production capacity ready. The distribution system \u2014 wholesalers, specialty distributors, GPO contracts \u2014 takes time to adapt to a new supplier landscape.<\/p>\n\n\n\n

      During that transition, shortage conditions can emerge even for products with multiple approved generic manufacturers. The FDA’s shortage database and the American Society of Health-System Pharmacists (ASHP) shortage reporting service both track active and resolved shortages with drug-specific detail. Incorporating shortage history into pre-LOE sourcing analysis tells you which product categories carry elevated shortage risk at LOE.<\/p>\n\n\n\n

      Sterile injectable generics are the highest-risk category. The manufacturing complexity, capital cost, and FDA inspection burden of sterile manufacturing create barriers to entry that commodity pricing doesn’t easily overcome. When a sterile injectable product loses exclusivity, the number of ANDA filers is typically much smaller than for an equivalent oral solid-dose product, and first-to-market supply constraints are more likely.<\/p>\n\n\n\n

      API Sourcing Concentration and the Real Cliff Risk<\/strong><\/h3>\n\n\n\n

      Behind the finished generic dosage form is an API supply chain that is itself highly concentrated. For many drug categories, a small number of manufacturers \u2014 disproportionately located in India and China \u2014 supply the active ingredient that all downstream generic finished-dose manufacturers use. When API supply for a particular compound is concentrated in two or three producers, a quality hold at any one of them ripples downstream to finished-dose generics across multiple brand names [34].<\/p>\n\n\n\n

      FDA’s Drug Administration Communication system publishes API shortage notices that procurement teams can monitor for early warning of upstream supply disruptions. The more sophisticated procurement organizations have integrated API supply monitoring into their shortage early-warning systems, tracking not just finished-dose availability but the API supply chain behind it.<\/p>\n\n\n\n

      GPO Contract Architecture for the Post-Cliff Market<\/strong><\/h3>\n\n\n\n

      Group purchasing organizations provide pharmacy contract frameworks that simplify supplier negotiations for member health systems, but the GPO contract structure has its own cliff-related dynamics that procurement teams should understand explicitly.<\/p>\n\n\n\n

      GPO contracts for generic drugs typically work through dual-award or multi-award tier structures \u2014 primary and secondary suppliers designated by the GPO, with committed volume tiers tied to pricing levels. When a drug transitions from brand to generic, GPOs typically issue their first generic contract within weeks of FDA approval, with pricing negotiated based on the initial competitive landscape. As additional generics enter and prices fall further, GPO contracts are repriced on a schedule that may lag the market.<\/p>\n\n\n\n

      Health systems that rely exclusively on GPO contracting may not capture the most aggressive generic pricing available in the spot market. Many large health systems use GPO contracts as a price floor and supplement with direct negotiations on high-volume products. That hybrid approach requires internal pharmacy purchasing staff with the analytical capability to identify when direct negotiation offers better net pricing than the GPO tier \u2014 a judgment that requires real-time market price visibility, not just the GPO contract sheet.<\/p>\n\n\n\n

      \n\n\n\n

      Part IX: Regulatory and Policy Developments Reshaping the Cliff<\/strong><\/h2>\n\n\n\n

      The Inflation Reduction Act and Drug Price Negotiation<\/strong><\/h3>\n\n\n\n

      The Inflation Reduction Act of 2022 gave CMS the authority to negotiate Medicare Part D drug prices directly with manufacturers \u2014 a structural change that alters the economics of the patent cliff in ways that procurement teams need to integrate into their strategic models.<\/p>\n\n\n\n

      The negotiated prices, branded Maximum Fair Prices (MFPs), apply initially to a limited set of high-cost, single-source drugs with no generic or biosimilar competition. The first ten drugs selected for negotiation in 2023 were all small molecules or biologics with extended market exclusivity and high Medicare spend [35]. By 2030, the law expands the negotiation scope substantially.<\/p>\n\n\n\n

      For procurement purposes, the IRA creates two effects that require tracking. First, negotiated Medicare prices may create reference price pressure in commercial markets as health plans use MFPs as benchmarks for their own negotiations. Second, the law’s design incentivizes manufacturers to accelerate generic and biosimilar competition for some products to avoid negotiation applicability \u2014 a structural incentive that could accelerate certain LOE events.<\/p>\n\n\n\n

      The IRA also introduced a drug price inflation rebate \u2014 manufacturers whose Part B or Part D prices rise faster than the Consumer Price Index must pay rebates to CMS. That provision changes the economics of branded drug price increases in the years approaching patent expiration, because the inflation rebate liability now functions as a brake on the price escalation strategy that brands have historically used to maintain revenue as volume shifts to generics [36].<\/p>\n\n\n\n

      FDA Initiatives Affecting Generic Entry Speed<\/strong><\/h3>\n\n\n\n

      FDA has several active programs designed to accelerate generic entry for products with limited competition or no approved generics. The Drug Competition Action Plan (DCAP), launched in 2017 and expanded since, includes tools that directly affect patent cliff dynamics:<\/p>\n\n\n\n

      The Complex Drug Substances and Products initiative prioritizes ANDA review for complex products where the lack of approved generics reflects scientific challenges rather than insufficient market size. Products on the DCAP priority list receive dedicated regulatory review resources and benefit from FDA’s accumulated guidance on how to demonstrate bioequivalence for complex formulations [37].<\/p>\n\n\n\n

      The Competitive Generic Therapy (CGT) designation, authorized by FDARA in 2017, expedites review of ANDAs for drugs with limited or no approved generics, with the first CGT applicant receiving 180-day exclusivity analogous to the Paragraph IV first-filer exclusivity. For procurement teams, CGT designations are a signal that FDA has identified a product as an unmet generic competition opportunity \u2014 a useful leading indicator for sourcing pipeline planning.<\/p>\n\n\n\n

      FTC Oversight of Anticompetitive Patent Practices<\/strong><\/h3>\n\n\n\n

      The Federal Trade Commission has historically scrutinized patent-related practices that delay generic entry, including pay-for-delay (reverse payment) settlements, product hopping strategies, and the accumulation of regulatory and patent barriers that characterize the most aggressive evergreening approaches.<\/p>\n\n\n\n

      The Supreme Court’s 2013 ruling in FTC v. Actavis established that reverse payment settlements are not immune from antitrust scrutiny under the rule of reason, which gave the FTC a clearer legal framework for challenging settlements where the brand pays the generic to delay entry [38]. Post-Actavis settlement agreements have generally become more conservative \u2014 generic manufacturers and brands negotiate at-risk launch rights or shorter exclusivity extensions rather than pure payment-for-delay \u2014 but the FTC continues to challenge arrangements it views as anticompetitive.<\/p>\n\n\n\n

      For procurement teams, FTC actions against pay-for-delay settlements are a secondary intelligence signal: when the FTC sues over a settlement, it often means generic entry has been delayed from what patent expiration alone would have permitted, and the litigation outcome could unlock earlier sourcing opportunities.<\/p>\n\n\n\n

      \n\n\n\n

      Part X: Building the Procurement Intelligence Operation<\/strong><\/h2>\n\n\n\n

      The Patent Cliff Monitoring Workflow<\/strong><\/h3>\n\n\n\n

      A functional patent cliff monitoring operation for a large health system, PBM, or GPO has these components:<\/p>\n\n\n\n

      First, a current formulary inventory cross-referenced against the Orange Book. Every formulary product that has a brand equivalent should have its Orange Book patent and exclusivity record populated, including all listed patents with expiration dates and use codes. This is not a one-time project; it requires quarterly refresh as new patents are listed and existing patents expire.<\/p>\n\n\n\n

      Second, a litigation tracker for Paragraph IV challenges. For products where generics have filed Paragraph IV certifications, the litigation docket should be reviewed monthly for case milestones that affect the probability-weighted entry timeline. This doesn’t require in-house IP counsel \u2014 third-party litigation tracking services or DrugPatentWatch’s litigation monitoring features can provide the necessary alert infrastructure.<\/p>\n\n\n\n

      Third, an ANDA pipeline depth assessment for each priority product. ‘Priority’ is defined by spend impact: take the top 50 to 100 products by annual formulary spend, identify which have approaching LOE events within 36 months, and assess the number of approved and pending ANDAs for each. Products with five or more ANDA filers approaching a near-term expiration are high-confidence sourcing opportunities. Products with zero or one filer on a complex formulation require a different risk assessment.<\/p>\n\n\n\n

      Fourth, a formulary calendar integration so that the P&T committee’s agenda includes a standing patent expiration review item, timed to allow pre-authorization of generic equivalents before their market entry.<\/p>\n\n\n\n

      Fifth, a supplier relationship development program for generic manufacturers, particularly for sterile injectable and complex specialty products where supplier count is low. Procurement teams who have established relationships with qualified generic manufacturers \u2014 including pre-approval meetings, facility visits, and supply security conversations \u2014 are in a materially better contracting position when those manufacturers achieve FDA approval.<\/p>\n\n\n\n

      Metrics That Measure Cliff Performance<\/strong><\/h3>\n\n\n\n

      Procurement leadership should track patent cliff performance against specific measurable outcomes, not narrative milestones:<\/p>\n\n\n\n

      Days to formulary conversion from first generic availability:<\/strong> The number of days between FDA approval of the first generic equivalent and the date the formulary tier change becomes effective for members. Target should be 30 days or fewer for oral solid-dose products where no clinical review is required. Longer conversion timelines represent recoverable costs.<\/p>\n\n\n\n

      Generic dispensing rate (GDR) at 90 days post-LOE:<\/strong> For products with multi-source generic competition, GDR at 90 days is an operational measure of formulary management execution. A well-managed formulary should achieve 70\u201380% or higher generic dispensing rate for most oral solid-dose products within 90 days of multi-source entry.<\/p>\n\n\n\n

      Brand-to-biosimilar conversion rate at 180 days:<\/strong> For biologic products with available interchangeable biosimilars, the conversion rate at 180 days post-formulary change measures both the clinical transition program and the formulary architecture’s effectiveness.<\/p>\n\n\n\n

      Cost per member per month (PMPM) reduction attributable to LOE events:<\/strong> The dollar impact of patent cliff sourcing should be tracked as a specific line item in the pharmacy benefit financial reporting, separate from generic dispensing program performance. This attribution enables the organization to value its patent intelligence investment accurately.<\/p>\n\n\n\n

      Technology Platforms for Patent Intelligence<\/strong><\/h3>\n\n\n\n

      Beyond DrugPatentWatch, several platforms offer components of the analytical infrastructure a sophisticated procurement operation requires:<\/p>\n\n\n\n

      Clarivate’s Cortellis platform provides patent analytics integrated with clinical development pipeline data, which helps procurement teams understand whether a product approaching LOE has next-generation follow-on compounds in development \u2014 relevant for assessing whether the brand will pursue prescriber migration to a successor product.<\/p>\n\n\n\n

      Bloomberg Law’s patent litigation tracking, combined with its ANDA database, provides court docket monitoring and settlement alert capabilities that complement Orange Book data.<\/p>\n\n\n\n

      IQVIA’s prescription analytics give procurement teams actual dispensing volume data at the NDA\/product level, which calibrates the financial impact of formulary transitions against real-world utilization rather than estimated market statistics.<\/p>\n\n\n\n

      ASHP’s drug shortage database provides real-time shortage status monitoring that procurement teams can integrate with their LOE tracking to identify shortage risk at the time of cliff events.<\/p>\n\n\n\n

      \n\n\n\n

      Part XI: Real-World Case Studies<\/strong><\/h2>\n\n\n\n

      Atorvastatin (Lipitor): The Canonical Cliff Event<\/strong><\/h3>\n\n\n\n

      Pfizer’s atorvastatin calcium (Lipitor) lost U.S. patent protection in November 2011 after years of Paragraph IV litigation. The lead-up and aftermath remain the reference case for large-scale patent cliff management in procurement.<\/p>\n\n\n\n

      At peak, atorvastatin generated approximately $13 billion in annual U.S. net revenues for Pfizer [39]. The compound patent expiration had been known and tracked for years. Ranbaxy Laboratories was the first ANDA filer with Paragraph IV certification and received the 180-day exclusivity window, launching in November 2011. Pfizer launched an authorized generic simultaneously through Watson Pharmaceuticals (now Allergan) to compete with Ranbaxy’s exclusivity.<\/p>\n\n\n\n

      The 180-day exclusivity period ended in May 2012, after which multiple generics entered. By mid-2012, atorvastatin generic pricing had fallen to less than $10 per month in retail pharmacy \u2014 from a branded list price of more than $200 per month \u2014 and generic dispensing rates exceeded 85%.<\/p>\n\n\n\n

      Health systems and PBMs that had pre-negotiated generic supplier contracts, with formulary tier changes pre-authorized for the day of first generic availability, captured maximum savings immediately. Systems that waited for the LOE event to initiate sourcing left months of branded pricing on the table during the 180-day exclusivity window, when savings relative to brand were real but constrained by single-source dynamics.<\/p>\n\n\n\n

      Clopidogrel (Plavix): Litigation Strategy and Procurement Risk<\/strong><\/h3>\n\n\n\n

      Bristol-Myers Squibb and Sanofi’s clopidogrel (Plavix) provides a counterpoint to the Lipitor story. The clopidogrel compound patent was successfully challenged via Paragraph IV by Apotex, which launched at-risk in August 2006 \u2014 before the litigation concluded. BMS and Sanofi sought and received an injunction that halted Apotex’s at-risk launch within days, and Apotex was required to recall distributed product.<\/p>\n\n\n\n

      The litigation ultimately resolved in BMS\/Sanofi’s favor, and clopidogrel maintained exclusivity until May 2012, when the patent expired. At that point, multiple generics entered rapidly and pricing collapsed.<\/p>\n\n\n\n

      For procurement teams, the clopidogrel case illustrates two things: at-risk launches can be reversed, so procurement plans built around a specific launch event should include contingency protocols; and when exclusivity is finally lost on a high-volume blockbuster after years of litigation, the scale of savings can be captured in a compressed timeframe \u2014 generic dispensing for clopidogrel hit 90% within months of multi-source availability [7].<\/p>\n\n\n\n

      Adalimumab (Humira): The Biologic Transition Blueprint<\/strong><\/h3>\n\n\n\n

      The 2023 adalimumab biosimilar launches are the biosimilar case study that procurement teams should study in detail, because the market structure lessons apply to every future large-molecule cliff event.<\/p>\n\n\n\n

      Seven biosimilar adalimumab products launched in 2023, with a mix of interchangeable and non-interchangeable designations, high-concentration and low-concentration formulations, and dramatically different pricing strategies [23]. AbbVie responded with its own Humira price adjustments and an escalated rebate program that made staying on Humira financially attractive to some PBMs.<\/p>\n\n\n\n

      The procurement outcomes tracked by IQVIA and Pembroke Consulting showed significant variation in biosimilar adoption rates across plan types, with Medicare Part D plans showing higher biosimilar conversion than commercial plans \u2014 a consequence of Part D’s formulary architecture and the IRA’s biosimilar incentives [40]. Health plans that pre-negotiated biosimilar contracts, pre-authorized formulary tier changes, and educated their member services and clinical teams on switching protocols achieved conversion rates approaching 40\u201350% within the first year. Plans that left the decision to PBM formulary management without active engagement achieved lower conversion.<\/p>\n\n\n\n

      The financial differential is substantial: at an 80% biosimilar discount to Humira’s list price, a plan with 1,000 adalimumab patients and average annual drug cost of $25,000 per patient saves $20 million annually at full biosimilar conversion versus $0 at no conversion. The first year of the adalimumab biosimilar market demonstrated that procurement engagement \u2014 not just formulary architecture \u2014 determines how much of that theoretical saving actually materializes.<\/p>\n\n\n\n

      \n\n\n\n

      Part XII: Building the Team and the Case Internally<\/strong><\/h2>\n\n\n\n

      Who Owns Patent Cliff Intelligence?<\/strong><\/h3>\n\n\n\n

      In most pharmacy benefit organizations, clinical, contracting, and drug intelligence functions operate with some degree of separation. Patent cliff intelligence sits at the intersection of all three without cleanly belonging to any of them \u2014 which means it often doesn’t get owned systematically.<\/p>\n\n\n\n

      The most effective organizational structures assign ownership explicitly. A Pharmacy Strategy function \u2014 distinct from both the clinical P&T support function and the contracting negotiation function \u2014 can own the prospective patent expiration calendar, the ANDA pipeline assessments, and the formulary transition scheduling. That function reports intelligence to contracting (to inform negotiation timing), to P&T (to schedule formulary reviews), and to finance (to inform drug spend projections).<\/p>\n\n\n\n

      For health systems without the scale to justify a dedicated function, the same analytical work can be structured as a quarterly deliverable from the pharmacy purchasing manager to the P&T committee and CFO, supported by external data tools that reduce the research burden.<\/p>\n\n\n\n

      Making the Business Case to Leadership<\/strong><\/h3>\n\n\n\n

      Pharmacy procurement’s difficulty in getting executive attention for patent cliff management stems partly from attribution challenges. When you save money by converting a formulary to generic the day after LOE, it’s not obvious that the saving required advance work rather than simply occurring naturally. The narrative needs to be built explicitly.<\/p>\n\n\n\n

      A useful framing is the opportunity cost of reactive sourcing: estimate the monthly savings available from multi-source generic pricing on a target product, then estimate the number of months of reactive lag typical in the organization \u2014 the time from FDA approval to actual formulary generic tier placement. Multiply those together across your top 20 LOE events in the next 36 months. The resulting number, even with conservative assumptions, typically justifies the investment in prospective intelligence infrastructure.<\/p>\n\n\n\n

      For a mid-sized health system spending $150 million annually on pharmaceuticals, the difference between capturing generic conversion in 30 days versus 120 days post-LOE across a portfolio of 20 products with collective spend of $30 million annually can represent $5\u201310 million in recoverable cost over a 36-month planning horizon.<\/p>\n\n\n\n

      \n\n\n\n

      Key Takeaways<\/strong><\/h2>\n\n\n\n

      Patent cliff events are predictable, not surprising.<\/strong> Orange Book expiration data, Paragraph IV litigation dockets, and ANDA pipeline depth are public and trackable. Procurement teams that haven’t built a prospective expiration calendar have chosen reactive sourcing by default.<\/p>\n\n\n\n

      The sourcing window is pre-LOE, not post-LOE.<\/strong> Initiating RFPs and generic supplier qualification 6\u201312 months before expiration captures better pricing and supply security than post-LOE scrambles. Pre-authorizing formulary tier changes speeds conversion from weeks to days.<\/p>\n\n\n\n

      Small molecules and biologics require different playbooks.<\/strong> The ANDA pathway, 30-month stay mechanics, and multi-source price dynamics apply to small molecules. Biosimilars involve BPCIA patent dances, interchangeability designations, and a formulary conversion process that requires clinical engagement \u2014 not just administrative tier changes.<\/p>\n\n\n\n

      DrugPatentWatch and Orange Book data are complementary, not redundant.<\/strong> Orange Book is the authoritative source; DrugPatentWatch adds litigation context, ANDA pipeline counts, and probabilistic timeline modeling that administrative patent databases don’t provide.<\/p>\n\n\n\n

      The 180-day exclusivity window is a sourcing opportunity, not a waiting period.<\/strong> A single generic competitor doesn’t produce commodity pricing, but it does produce measurable savings over branded prices. Pre-negotiating with first-filer generics before exclusivity opens captures that value.<\/p>\n\n\n\n

      Supplier concentration is the long-term cliff risk that outlasts the immediate price event.<\/strong> Multi-source generic markets that initially look competitive can consolidate to two or three producers within five years, creating shortage vulnerability. Dual-source contracting is supply chain insurance, not procurement inefficiency.<\/p>\n\n\n\n

      The biologic patent cliff is structurally longer and more complex than small-molecule cliffs.<\/strong> Twelve-year reference product exclusivity, patent thickets, and interchangeability designation requirements make biologic LOE planning a multi-year exercise. Starting that work three years before projected LOE is not early \u2014 it’s the minimum lead time for complex formulary transitions.<\/p>\n\n\n\n

      IRA provisions are changing the economics of drug pricing approaching LOE.<\/strong> Medicare negotiated prices, inflation rebates, and biosimilar Part B payment differentials all affect the financial calculus of patent cliff sourcing. Procurement models built entirely on pre-IRA assumptions need updating.<\/p>\n\n\n\n

      \n\n\n\n

      FAQ<\/strong><\/h2>\n\n\n\n

      Q1: Can a procurement team legally receive advance notice of generic launch dates from manufacturers before FDA approval?<\/strong><\/p>\n\n\n\n

      A: In general terms, yes \u2014 ANDA applicants routinely discuss anticipated launch timelines with potential customers to support commercial planning, and nothing in Hatch-Waxman prohibits those conversations. What’s prohibited is launching a product before FDA approval (absent an explicit at-risk launch decision by the manufacturer). Procurement teams can and do sign confidentiality agreements with generic manufacturers to receive more detailed pipeline information before public announcement, particularly for complex products where supply ramp planning is critical. The practical constraint is that no manufacturer can guarantee an FDA approval date with certainty, so any pre-approval commitments need appropriate contingency terms.<\/p>\n\n\n\n

      Q2: How should a procurement team handle a product where multiple biosimilars are available but none has achieved interchangeable status?<\/strong><\/p>\n\n\n\n

      A: Formulary management without interchangeability requires prescriber engagement rather than pharmacist-level substitution. The practical approach is a structured outreach program to high-volume prescribers, explaining the biosimilar options and the evidence supporting switching, combined with a formulary design that places interchangeable-pending biosimilars on a preferred tier for new patients while managing existing stable patients on a case-by-case basis. Clinical protocols should define what monitoring, if any, is appropriate during a non-interchangeable switch \u2014 particularly for immunology and oncology patients where disease monitoring is ongoing. Health plans that have successfully managed this have paired the formulary design with member communication, prescriber education, and a defined exception process for patients where a switch is clinically contraindicated.<\/p>\n\n\n\n

      Q3: What’s the best way to model the financial impact of a patent cliff event in a pharmacy budget?<\/strong><\/p>\n\n\n\n

      A: The model needs four inputs: current annual spend on the branded product, projected generic price as a percent of current branded AWP (typically 15\u201325% at multi-source entry for high-volume products), the expected generic dispensing rate at steady state (typically 85\u201390% for standard oral solid-dose, lower for complex formulations and biologics), and the expected time to reach that steady-state conversion (typically 6\u201312 months from first generic availability). The resulting calculation \u2014 current spend \u00d7 (1 – (generic price ratio \u00d7 GDR)) \u2014 gives you the steady-state annual saving relative to current spend. Discount that against a realistic conversion curve and add a sensitivity range for the uncertainty in generic pricing and conversion timing. For biologic cliff events, the same framework applies but with generic price ratios starting at 15\u201330% of branded list for initial biosimilar entry and conversion rates at 30\u201350% in the first year, reflecting the slower adoption dynamics documented in the adalimumab experience.<\/p>\n\n\n\n

      Q4: How does the 340B Drug Pricing Program interact with patent cliff events for covered hospitals?<\/strong><\/p>\n\n\n\n

      A: The 340B ceiling price for a covered outpatient drug is calculated as AMP minus a statutory discount. For branded drugs, AMP is set by the manufacturer; for generics, AMP is set by each generic manufacturer separately. When a product goes generic, the 340B ceiling price for the branded NDA product may still apply for purchases through that NDA, but the generic equivalents have their own AMP-based ceiling prices. In practice, the generic market price often falls below the 340B ceiling price within months of multi-source generic entry, meaning 340B-covered hospitals may find that generic WAC pricing is more favorable than their 340B entitlement on the branded product \u2014 effectively making the 340B benefit irrelevant for those products once robust generic competition exists. Covered entities should model this transition explicitly and adjust their purchasing strategy accordingly.<\/p>\n\n\n\n

      Q5: Are there specific therapy classes where patent cliff analysis consistently underperforms expectations, and how should procurement teams adjust?<\/strong><\/p>\n\n\n\n

      A: Two therapy classes consistently produce slower-than-expected generic market development: complex inhaled drug-device combinations and ophthalmic preparations. For inhaled products, the FDA’s device-inclusive bioequivalence requirements have historically delayed ANDA approvals well beyond compound patent expiration \u2014 generic fluticasone\/salmeterol (Advair), for example, took years longer than many analysts predicted to reach the market. For ophthalmics, particularly combination products and preservative-free formulations, ANDA development costs relative to market size have deterred generic filers. Procurement teams should apply a conservative adjustment to any cliff-based savings projection in these categories, extending the expected time to multi-source generic availability by 18\u201336 months beyond compound patent expiration and reducing expected GDR assumptions to 50\u201360% rather than the 80\u201390% typical of standard oral solid-dose generics.<\/p>\n\n\n\n

      \n\n\n\n

      References<\/strong><\/h2>\n\n\n\n

      [1] U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations<\/em> (44th ed.). FDA. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/orange-book-approved-drug-products-therapeutic-equivalence-evaluations<\/p>\n\n\n\n

      [2] Carrier, M. A. (2017). Skinny labels and the court’s missed opportunity in Teva v. Sandoz. Stanford Technology Law Review, 20<\/em>(1), 1\u201328.<\/p>\n\n\n\n

      [3] U.S. Food and Drug Administration. (2023). Pediatric exclusivity under the Best Pharmaceuticals for Children Act<\/em>. FDA Office of Pediatric Therapeutics. https:\/\/www.fda.gov\/science-research\/pediatric-drug-research\/pediatric-exclusivity<\/p>\n\n\n\n

      [4] Kesselheim, A. S., Wang, B., Franklin, J. M., & Darrow, J. J. (2013). Trends in utilization of FDA expedited drug development and approval programs, 1987\u20132014. JAMA, 311<\/em>(4), 378\u2013384.<\/p>\n\n\n\n

      [5] Evaluate Pharma. (2012). World preview 2018: Embracing the patent cliff<\/em>. Evaluate Ltd.<\/p>\n\n\n\n

      [6] IQVIA Institute for Human Data Science. (2024). The use of medicines in the United States 2024: Usage and spending trends and outlook to 2028<\/em>. IQVIA. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/the-use-of-medicines-in-the-us-2024<\/p>\n\n\n\n

      [7] Congressional Budget Office. (2021). Prices for and spending on specialty drugs in Medicare Part D and Medicaid<\/em>. CBO. https:\/\/www.cbo.gov\/publication\/57050<\/p>\n\n\n\n

      [8] Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, 124 Stat. 119 (2010). https:\/\/www.fda.gov\/media\/78946\/download<\/p>\n\n\n\n

      [9] Feldman, R. (2018). May your drug price be ever green. Journal of Law and the Biosciences, 5<\/em>(3), 590\u2013647. https:\/\/doi.org\/10.1093\/jlb\/lsy022<\/p>\n\n\n\n

      [10] Pembroke Consulting. (2024). Biosimilar adalimumab: First year market experience analysis<\/em>. Pembroke Consulting, Inc.<\/p>\n\n\n\n

      [11] Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act), Pub. L. No. 98-417, 98 Stat. 1585 (1984).<\/p>\n\n\n\n

      [12] U.S. Federal Trade Commission. (2011). Authorized generic drugs: Short-term effects and long-term impact<\/em>. FTC. https:\/\/www.ftc.gov\/reports\/authorized-generic-drugs-short-term-effects-long-term-impact<\/p>\n\n\n\n

      [13] DrugPatentWatch. (2025). Patent and exclusivity analysis for CGRP monoclonal antibodies<\/em>. DrugPatentWatch.com. https:\/\/www.drugpatentwatch.com<\/p>\n\n\n\n

      [14] U.S. Food and Drug Administration. (2024). Purple Book database of licensed biological products<\/em>. FDA. https:\/\/purplebooksearch.fda.gov\/<\/p>\n\n\n\n

      [15] IQVIA Institute for Human Data Science. (2023). Biosimilars in the United States 2023\u20132027: Competition, savings, and sustainability<\/em>. IQVIA. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/biosimilars-in-the-united-states-2023-2027<\/p>\n\n\n\n

      [16] U.S. Food and Drug Administration. (2024). Generic drug program 2023 annual report<\/em>. FDA Center for Drug Evaluation and Research. https:\/\/www.fda.gov\/media\/170485\/download<\/p>\n\n\n\n

      [17] U.S. Food and Drug Administration. (2023). GDUFA performance report: Fiscal year 2023<\/em>. FDA. https:\/\/www.fda.gov\/industry\/generic-drug-user-fee-amendments\/gdufa-performance-reports<\/p>\n\n\n\n

      [18] U.S. Food and Drug Administration. (2019, July 25). FDA approves first generic of Symbicort to treat asthma and COPD<\/em>. FDA News Release. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-generic-symbicort-treat-asthma-and-copd<\/p>\n\n\n\n

      [19] U.S. Food and Drug Administration. (2013, February 5). FDA approves first generic version of Doxil<\/em>. FDA News Release. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-generic-version-doxil<\/p>\n\n\n\n

      [20] Fein, A. J. (2023). Drug channels: 2023 economic report on U.S. pharmacies and pharmacy benefit managers<\/em>. Drug Channels Institute.<\/p>\n\n\n\n

      [21] American Society of Health-System Pharmacists. (2024). ASHP national drug shortage survey report 2024<\/em>. ASHP Research and Education Foundation.<\/p>\n\n\n\n

      [22] AbbVie Inc. (2022). AbbVie 2021 annual report<\/em>. AbbVie Inc. https:\/\/investors.abbvie.com\/financial-information\/annual-reports<\/p>\n\n\n\n

      [23] U.S. Food and Drug Administration. (2023). Biosimilar product information: Adalimumab<\/em>. FDA. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information<\/p>\n\n\n\n

      [24] IQVIA Institute for Human Data Science. (2024). Adalimumab biosimilar adoption: One year market assessment<\/em>. IQVIA.<\/p>\n\n\n\n

      [25] Novo Nordisk A\/S. (2024). Annual report 2023<\/em>. Novo Nordisk. https:\/\/www.novonordisk.com\/content\/dam\/nncorp\/global\/en\/investors\/nnit\/2024\/novo-nordisk-annual-report-2023.pdf<\/p>\n\n\n\n

      [26] Eli Lilly and Company. (2024). Tirzepatide: Product patent summary for Mounjaro and Zepbound<\/em>. Eli Lilly corporate communications.<\/p>\n\n\n\n

      [27] U.S. Food and Drug Administration. (2024, October). FDA updates on compounding of semaglutide and tirzepatide<\/em>. FDA Drug Shortages. https:\/\/www.fda.gov\/drugs\/drug-shortages\/compounding-semaglutide-and-tirzepatide-products<\/p>\n\n\n\n

      [28] Lyman, G. H., Balaban, E., Diaz, M., & Ferris, A. (2018). American Society of Clinical Oncology statement: Biosimilars in oncology. Journal of Clinical Oncology, 36<\/em>(12), 1260\u20131265. https:\/\/doi.org\/10.1200\/JCO.2017.77.4893<\/p>\n\n\n\n

      [29] Hernandez, I., Sampathkumar, S., Good, C. B., Gellad, W. F., & Shrank, W. H. (2020). Association of manufacturer rebates and out-of-pocket costs for commercially insured patients receiving brand-name medications. JAMA Internal Medicine, 180<\/em>(6), 892\u2013896.<\/p>\n\n\n\n

      [30] Cohen, H., Beydoun, D., Chien, D., Lessor, T., McCabe, D., Muenzberg, M., Popovian, R., & Rao, D. (2016). Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Advances in Therapy, 33<\/em>(12), 2160\u20132172.<\/p>\n\n\n\n

      [31] European Medicines Agency. (2023). Procedural aspects related to scientific advice on biosimilar medicines<\/em>. EMA\/CHMP\/BWP\/49348\/2005 Rev. 4.<\/p>\n\n\n\n

      [32] U.S. Food and Drug Administration. (2023). FDA’s human drug imports from India: Summary of fiscal year 2022 import data<\/em>. FDA Office of Regulatory Affairs.<\/p>\n\n\n\n

      [33] Alpern, J. D., Stauffer, W. M., & Kesselheim, A. S. (2014). High-cost generic drugs \u2014 implications for patients and policymakers. New England Journal of Medicine, 371<\/em>(20), 1859\u20131862. https:\/\/doi.org\/10.1056\/NEJMp1408696<\/p>\n\n\n\n

      [34] Woodcock, J., & Wosinska, M. (2013). Economic and technological drivers of generic sterile injectable drug shortages. Clinical Pharmacology & Therapeutics, 93<\/em>(2), 170\u2013176. https:\/\/doi.org\/10.1038\/clpt.2012.220<\/p>\n\n\n\n

      [35] Centers for Medicare & Medicaid Services. (2024). Medicare drug price negotiation program: Selected drugs for initial price applicability year 2026<\/em>. CMS. https:\/\/www.cms.gov\/inflation-reduction-act\/medicare-drug-price-negotiation<\/p>\n\n\n\n

      [36] Kaiser Family Foundation. (2023). How the Inflation Reduction Act’s Medicare drug pricing provisions will work<\/em>. KFF. https:\/\/www.kff.org\/medicare\/issue-brief\/how-the-inflation-reduction-acts-medicare-drug-pricing-provisions-will-work<\/p>\n\n\n\n

      [37] U.S. Food and Drug Administration. (2022). Drug competition action plan: Progress report<\/em>. CDER. https:\/\/www.fda.gov\/drugs\/generic-drugs\/drug-competition-action-plan<\/p>\n\n\n\n

      [38] Federal Trade Commission v. Actavis, Inc., 570 U.S. 136 (2013).<\/p>\n\n\n\n

      [39] Pfizer Inc. (2012). Pfizer 2011 annual report<\/em>. Pfizer Inc. https:\/\/www.pfizer.com\/investors\/reports-and-filings\/annual-reports<\/p>\n\n\n\n

      [40] IQVIA Institute for Human Data Science. (2024). Biosimilar market dynamics: Adalimumab case study and implications for future biologics<\/em>. IQVIA.<\/p>\n","protected":false},"excerpt":{"rendered":"

      How to turn expiring blockbusters into budget wins \u2014 before your competitors do Patent cliffs don’t sneak up on anyone. […]<\/p>\n","protected":false},"author":1,"featured_media":38542,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38537","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38537"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38537\/revisions"}],"predecessor-version":[{"id":38543,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38537\/revisions\/38543"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38542"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}